Redeye: Calliditas Therapeutics: Study design change - reduced costs and timeline

In this research update, we provide you with our view on the updated Nefigard part-B trial.

Read more and download the analysis: http://bit.ly/2I4m8Gj

Start following companies at Redeye to recieve the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/